Diagnostic Ionizing Radiation Exposure in a Population-Based Sample of Children With Inflammatory Bowel Diseases by Palmer, Lena et al.
Diagnostic Ionizing Radiation Exposure in a Population-based
Sample of Children with Inflammatory Bowel Diseases
Lena Palmer, MD, MSCR1, Hans Herfarth, MD, PhD1, Carol Q. Porter2, Lynn A. Fordham,
MD3, Robert S. Sandler, MD, MPH1, and Michael D. Kappelman, MD, MPH4
1Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina
at Chapel Hill, Chapel Hill, NC
2Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill,
Chapel Hill, NC
3Department of Radiology, University of North Carolina Chapel Hill, Chapel Hill, NC
4Department of Pediatrics, Division of Gastroenterology, University of North Carolina at Chapel Hill,
Chapel Hill, NC
Abstract
Background and Aims—The degree of diagnostic radiation exposure in children with
inflammatory bowel diseases (IBD) is largely unknown. Here we describe this exposure in a
population-based sample of children with IBD and determine characteristics associated with
moderate radiation exposure.
Methods—We ascertained radiological study use, demographic characteristics, IBD medication
use, and the requirement for hospitalization, emergency department (ED) encounter, or inpatient GI
surgery among children with IBD within a large insurance claims database. Characteristics associated
with moderate radiation exposure (at least one computed tomography (CT) or three fluoroscopies
over two years) were determined using logistic regression models.
Results—We identified 965 children with Crohn’s Disease (CD) and 628 with Ulcerative Colitis
(UC). Over 24 months, 34% of CD subjects and 23% of UC subjects were exposed to moderate
diagnostic radiation [odds ratio (OR) 1.71, 95% confidence interval (CI), 1.36–2.14]. CT accounted
for 28% and 25% of all studies in CD and UC subjects, respectively. For CD subjects, moderate
Information for correspondence: Lena Palmer, MD, MSCR, University of North Carolina at Chapel Hill, Department of Medicine,
Division of Gastroenterology and Hepatology, 130 Mason Farm Road, 4162R Bioinformatics Building, Campus Box 7080, Chapel Hill,
NC 27599, Phone: (919) 966-2541, Fax: (919) 966-6842, lena_palmer@med.unc.edu.
Guarantor of the article: Dr. Palmer is the guarantor of the article and takes full responsibility for the conduct of the study.
Specific author contributions:
Dr. Palmer participated in the conception and design of the study, data preparation, data analysis, and manuscript preparation. She was
involved in final document editing and has approved the final draft submitted.
Dr. Herfarth participated in the conception and design of the study. He was involved in final document editing and has approved the final
draft submitted.
Ms. Porter provided data abstraction and dataset preparation services. She was involved in final document editing and has approved the
final draft submitted.
Dr. Fordham participated in the conception and design of the study. She was involved in final document editing and has approved the
final draft submitted.
Dr. Sandler participated in the conception and design of the study. He was involved in final document editing and has approved the final
draft submitted.
Dr. Kappelman participated in the conception and design of the study, as well as data analysis. He was involved in final document editing
and has approved the final draft submitted.
Potential competing interests: No authors have a competing interest to disclose.
NIH Public Access
Author Manuscript
Am J Gastroenterol. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:













radiation exposure was associated with hospitalization (OR 4.89, 95% CI 3.37–7.09), surgery (OR
2.93, 95% CI 1.59–5.39), ED encounter (OR 2.65, 1.93–3.64 95% CI), oral steroids (OR 2.25, 95%
CI 1.50–3.38), and budesonide (OR 1.80, 95% CI 1.10–3.06); an inverse association was seen with
immunomodulator use (OR 0.67, 95% CI 0.47–0.97). Except for oral steroids and
immunomodulators, similar relationships were seen in UC.
Conclusion—A substantial proportion of children with IBD are exposed to moderate amounts of
radiation as a result of diagnostic testing. This high utilization may impart long-term risk given the
chronic nature of the disease.
INTRODUCTION
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease
(CD), are chronic, autoimmune diseases of the intestines that can begin in childhood. Both
follow a fluctuating, life-long course with multiple acute episodes or “flares” interspersed
between periods of quiescence. Advances in the treatment of IBD have led to novel therapeutics
that may alter the course of the disease. However, individuals with IBD have an increased-risk
of developing various malignancies, both from the disease itself and from therapeutics used to
treat the disease.(1–5)
Diagnostic imaging, including the use of radiological tests such as fluoroscopy and computed
tomography (CT), has become an increasingly important component of the evaluation and
management of IBD. However, diagnostic ionizing radiation represents an additional IBD-
related exposure with carcinogenic potential.(6,7) Of particular concern is CT, which can
impart radiation doses that are over 100 times that of a conventional x-ray film.(8) Ionizing
radiation increases the risk of several types of malignancies, including hematologic and solid-
organ cancers. Observational studies of atomic bomb and nuclear disaster survivors as well as
radiation industry workers have demonstrated an increased-risk of death from malignancy with
even moderate exposures.(9–12) Low-level, protracted radiation exposures (such as those
associated with medical imaging) have also been associated with malignancy.(9,13–16)
The pediatric population is particularly vulnerable to the effects of ionizing radiation.(11,17)
Compared to adults, children have more biologically active tissue with less intervening space
between susceptible organs. In addition, they have a lifetime in which to develop radiation-
induced complications. Consequently, it has been estimated that the ionizing radiation imparted
in one computed tomography before the age of 15 incurs a 1 in 1500 excess risk of cancer
mortality.(18)
Despite these risks of radiation, the use of CT has increased in the general United States (US)
population by approximately twenty-fold over the last twenty-five years.(8) Even more
concerning is that between 6% and 11% of CT scans in the US are performed in children,
(19) the subgroup of the population with the highest risk. Several recent studies have
documented that the utilization of CT in adult IBD patients has far outpaced CT utilization in
the general population. One tertiary IBD referral center demonstrated a 380% increase in the
use of CT over a fifteen year period,(7) and another population-based investigation reported
an 870% increase in the use of CT enterography.(20) However, the utilization of diagnostic
ionizing radiation in US children with IBD remains poorly characterized.
Given the exponential increase in diagnostic radiation exposure by adult IBD patients, and the
particular concern for malignancy risk in pediatric patients, we sought to describe the utilization
of diagnostic ionizing radiation in a population-based sample of children with UC and CD. We
also examined the patient characteristics associated with moderate dose imaging exposure.
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Study Design and Data Source
In this cross-sectional study, we analyzed the medical, surgical, and pharmaceutical insurance
claims contained in the PharMetrics© Patient-Centric Database (IMS Health, Watertown, MA)
for the period January 1, 2003 through December 31, 2004. Prior studies have used this
longitudinal, patient-level database to examine the prevalence and costs of IBD.(21) At the
time of this study, the PharMetrics database included claims from 87 health plans in 33 states
and was reported to be representative of the national commercially-insured population on a
variety of demographic measures, including geographic region, age, gender, and health plan
type.(22)
Patient Selection
All children age 18 and under at the time of identification with continuous health plan
enrollment between January 1, 2003 and December 1, 2004 were eligible for inclusion in this
analysis. We identified cases of UC and CD using a previously described administrative claims
ascertainment algorithm.(21) This definition included patients with at least three health care
contacts, on different days, associated with an International Classification of Diseases, 9th
Revision, (ICD-9) Clinical Modification diagnosis code for UC (556.xx) or CD (555.xx), or
patients with at least one claim for UC or CD and at least one pharmacy claim for any of the
following medications: mesalamine, osalazine, balsalazide, sulfasalazine, 6-mercaptopurine,
azathioprine, infliximab, adalimumab, and enteral budesonide. For patients who had claims
for both UC and CD, disease assignment was made according to the majority of the last 9
claims.
Exposure Ascertainment
To determine outcomes and exposures of interest, we classified each claim as inpatient,
outpatient, or pharmaceutical according to Current Procedural Terminology (CPT), Healthcare
Common Procedure Coding System (HCPCS), or National Drug Codes (NDC). We identified
several exposures of interest within our study population, including age, gender, geographical
region (Northeast, South, Midwest, and West), the requirement for hospitalization with a
primary diagnosis of UC (556.xx) or CD (555.xx), emergency department (ED) encounters
that did not result in hospitalization, and the requirement for inpatient gastrointestinal (GI)
surgery (one or more claims during a period of any-cause hospitalization that contained a
procedure code for a gastrointestinal operation, excluding surgery of the liver, biliary tract, and
pancreas).
We also examined patient exposure to IBD-specific medical therapy, including oral or rectal
salicylates (mesalamine, osalazine, balsalazide, or sulfasalazine), immunomodulators (6-
mercaptopurine, azathioprine, or methotrexate), anti-TNF alpha agents (infliximab or
adalimumab), oral steroids, and enteral-release budesonide. Subjects were considered exposed
to medical therapy if they had at least 2 pharmacy claims for the medications over the time of
the study.
Outcome Description
All occurrences of 23 different types of diagnostic imaging studies were identified via CPT
codes, including CT of the abdomen and/or pelvis; CT angiogram (CTA) of the abdomen,
mesentery, or aorta; CT enterography; abdominal X-ray, fistulogram or sinogram; upper GI
series; upper GI series with small-bowel follow-through; small-bowel follow-through without
upper GI series; contrast enema; endoscopic retrograde cholangiopancreatography (ERCP),
cholangiography or cholecystography; small bowel enteroclysis, as well as selected non-GI
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studies. A complete list of CPT classification codes is included in the supplemental material
(See Supplementary Table 1 online). Due to the fact that that multiple claim lines are often
submitted for a single encounter (facility fees, technical services, professional services, etc),
we counted all claims for the same type of imaging test occurring on the same day as a single
study. When both a CT of the abdomen and a CT of the pelvis occurred on the same day, they
were counted as a single abdomino-pelvic CT.
Moderate dose radiation imaging was defined as at least one CT or three fluoroscopic
procedures during the two-year observation period. We based this definition upon data from
the atomic bomb survivor cohort indicating that the ionizing radiation dose imparted by one
abdominal CT prior to the age of 15 carries a 1 in 1500 risk of death from malignancy, with
risk falling logarithmically into one’s third decade of life.(18) Also, published estimates of
fluoroscopic and CT effective doses indicate that, on average, fluoroscopic procedures impart
lower doses of ionizing radiation than CT scans.(23–28) CT scans impart one-hundred to one-
hundred fifty times the dose of one conventional X-ray or bone mineral density exam; therefore,
X-rays and bone mineral density exams were not included in the definition of moderate dose
radiation imaging.(20,29)
Statistical Analysis
Standard univariate statistics were performed, including calculations of means, medians,
proportions, ranges and interquartile ranges. The one continuous variable, age, was examined
in its simple continuous form as well as categorical forms in order to determine the most valid
and precise coding structure. Bivariate statistics (Pearson’s chi-square, Wilcoxon rank-sum,
or t-tests based on variable type) were used to assess for statistical associations between the
receipt of moderate radiation imaging and the exposures of interest.
Multivariable logistic regression models estimating prevalence odds ratios were performed
separately within the UC and CD samples. Methotrexate, azathioprine, and 6-mercaptopurine
were analyzed as “immunomodulators”, and adalimumab and infliximab were analyzed as
“anti-TNF alpha agents”. Adalimumab, infliximab, and budesonide were used rarely to treat
UC at the time of the study and were excluded from the UC model. Each exposure was
considered of potential interest; therefore, all potential risk factors were retained in the final
model. Stata statistical software (Stata Ver. 10.0, College Station, Texas) was used for all
statistical analyses. The study protocol was granted exemption from review by the Institutional
Review Board at the University of North Carolina at Chapel Hill on September 9, 2008, because
it involved the use of existing, de-identified data.
RESULTS
Sample Characteristics
We identified 1593 children with IBD (628 UC and 965 CD). The mean age was 14 years, with
a standard deviation of 3 years [Table 1]. Forty-five percent of the sample was female, and
patients were relatively evenly divided among the four regional areas (34.2% Northeast, 16.8%
West, 21.4% South, and 27.6% Midwest). The only statistical differences between the UC and
CD groups were in the use of IBD specific medications. More children with CD were exposed
to immunomodulators (43% versus 26%, p<0.05), anti-TNF alpha agents (15.4% versus 3.2%,
p<0.05) and budesonide (9% versus 4%, p<0.05). Conversely, more children with UC were
exposed to rectal salicylates (26% versus 6%, p<0.05). Approximately one-quarter of the
sample was hospitalized at least once over the two-year period, 37% had at least one emergency
department encounter that did not result in hospitalization, and 8% underwent an inpatient GI
surgery.
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Over the two year period, 23% of children with UC and 34% of children with CD were exposed
to moderate radiation imaging [odds ratio (OR) 1.71, 95% confidence interval (CI), 1.36–2.1].
Forty-nine percent of UC subjects and 33% of CD subjects received no imaging studies. There
was a median of 1 CT, 1 fluoroscopy, and 2 x-rays in the group who were exposed to any
imaging. When we examined the distribution by study type, x-ray exams (plain film exams of
chest, abdomen, or pelvis, and bone mineral density exams) were the most commonly ordered
study (60% of imaging in UC; 48% in CD) [Figure 1]. CT comprised 25% of all studies ordered
for children with UC and 28% of all studies ordered for children with CD. Fluoroscopic
procedures were the least-commonly performed study (16% of imaging in UC; 23% in CD).
Six percent of CD subjects and 5% of UC subjects underwent 3 or more CT scans, and 1.8%
of CD subjects and 2.2% of UC subjects underwent 5 or more CT scans. Detailed utilization
of all imaging studies over the two year period is shown in Table 2 and Table 3.
Factors associated with moderate radiation imaging
The results of multivariable regression modeling for children with CD demonstrate that IBD-
related hospitalization (OR 4.89, 95% CI 3.37–7.09), inpatient GI surgery (OR 2.93, 95% CI
1.59–5.39), use of oral steroids (OR 2.25, 95% CI 1.50–3.38), ED encounter (OR 2.65, 1.93–
3.64 95% CI), and use of enteral budesonide (OR 1.80, 95% CI 1.10–3.06) were positively
associated with the receipt of moderate dose radiation imaging, and immunomodulators were
negatively associated (OR 0.67, 95% CI 0.47–0.97)[Table 4]. When we stratified our results
by oral steroid use (a marker of disease flare), we found the inverse association with
immunomodulator use was only present in those patients who did not require steroids during
the observation period (unexposed to steroids: OR 0.55, 95% CI 0.36–0.85; exposed to steroids
1.36, 95% CI 0.62–2.99). Similar point estimates were seen in subjects with UC, though the
only statistically significant associations were IBD-related hospitalization (OR 3.04, 95%CI
1.84–5.03), surgery (OR 4.13, 95%CI 1.85–9.22), and ED encounter (OR 3.27, 95%CI 2.13–
5.01) [Table 4].
Age, gender, use of anti-TNF agents and use of oral or rectal salicylates were not associated
with diagnostic radiation exposure in UC or CD. Regional variation was modest [Table 4].
We repeated the analyses using a definition of moderate dose radiation exposure as at least one
CT or two fluoroscopic studies over the two year period. This resulted in an additional 29
children with CD (2%) and 11 children with UC (2%) classified as receiving moderate dose
radiation exposure. The addition of these patients did not change the effect estimates in our
multivariable models.
Imaging performed in patients without obvious risk factors may represent "overuse"(30) of
radiological testing, and thus unnecessary radiation exposure. Therefore, we sought to further
characterize the use of radiological studies in patients without hospitalization, surgery, ED
encounters, and oral steroid use. In this low risk group, 13% of children with CD and 7% of
children with UC received moderate radiation exposure through diagnostic imaging.
DISCUSSION
This population-based analysis has demonstrated that approximately one-third of
commercially insured US children with CD and one quarter with UC were exposed to at least
moderate amounts of diagnostic ionizing radiation over a two-year time period. Indicators of
severe disease are associated with increased imaging, including hospitalization, surgery, ED
encounters, and use of steroids. The use of immunomodulators is negatively associated with
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radiation exposure in children with CD, which may reflect the growing body of literature
demonstrating that immunomodulators are effective in maintaining disease remission.(31,32)
The widespread use of CT and other imaging modalities in pediatric IBD patients is consistent
with the emerging literature in this area. Newnham and colleagues were the first to highlight
the use of diagnostic radiation exposure in IBD patients.(6) They reported the imaging history
of 62 subjects with CD and 48 subjects with UC (mean age 39 years, range 16–84 years) at a
single, tertiary-care IBD referral center in Australia. Using a definition of “high risk” exposure
as a cumulative dose greater than 50 mSv, they estimated that 11% of their sample was exposed
to high levels of diagnostic ionizing radiation. Factors associated with high-level exposure
included a diagnosis of CD versus UC (OR for UC 0.33, 95% CI 0.05–2.01) and undergoing
surgery (OR 3.01, 95% CI 0.67–13.5). These results were not significant overall, likely due
the small sample size of the study.
Two additional studies have confirmed these findings and have demonstrated the increase in
CT use over time. One tertiary referral center in Ireland reported an increase in use of CT by
380% from the period spanning 1992–1997 to the period spanning 2002 to 2007. Peloquin and
colleagues performed a population-based analysis of diagnostic radiation exposure in IBD
patients in Olmstead County, Minnesota,(20) and also demonstrated a large increase in CT
utilization.
Our study extends this prior work in a number of meaningful ways. First, we focus solely on
pediatric patients. This population, which has been largely neglected in prior studies, is actually
the most vulnerable to the harmful effects of radiation exposure. We found that CT comprised
a significant proportion of imaging tests performed in pediatric IBD patients, particularly in
children with CD. This partly explains the high proportion of children exposed to moderate
ionizing radiation over the 24 month observation period. In addition, CT was used more often
in this pediatric cohort than has been seen in studies of adults (up to 28% in our pediatric
population versus 12% to 16% in adults (6,7)). A cohort effect based on the years of study is
unlikely to explain this finding as the two years of our analysis fell between the study periods
of the adult reports. The higher utilization of CT (and exposure to radiation) observed in
pediatric patients as compared to adult patients may related to the increased severity and extent
of disease in children compared with adults, as suggested in a number of recent reports.(33,
34) Alternatively, increased imaging may be a function of time-from-diagnosis. Prior work
from Longobardi et al has demonstrated that healthcare resource utilization is most intense in
the 2 years following diagnosis.(35,36) Children are more likely than adults to be closer to
their time of diagnosis and potentially more likely to undergo imaging. Also, providers may
view diagnostic medical imaging as non-invasive and therefore choose radiation-based tests
before other strategies involving more immediate risks from sedation, biopsies, etc.
Despite the growing public health concern over the expanding use of high-dose diagnostic
radiation, awareness of the risks is low among medical providers and patients. In a 2004 study
of abdominal CT imaging in a US emergency department, 97% of patients, 91% of emergency
medicine physicians and 53% of radiologists did not believe that CT studies could increase the
risk of malignancy.(37) Only 7% of patients remembered discussing radiation risks prior to
the exam. Practitioners in Great Britain demonstrated a similarly poor knowledge of radiation
risks.(38) This suggests that while concerns for malignancy are of paramount importance with
regards to therapeutic decision making, they do not appear to be a high priority with regards
to diagnostic decision making.
The data presented here indicate that a substantial proportion of children with IBD are exposed
to potentially harmful amounts of ionizing radiation as a result of diagnostic testing. Therefore,
as with therapeutic decisions, we advocate that the risks, benefits, and alternatives to
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fluoroscopic and CT studies be carefully considered. Emerging diagnostic alternatives to these
studies include ultrasound and newer MRI imaging modalities where available.(39,40)
Furthermore, a "watch and wait" approach with serial abdominal exams may also be helpful
in identifying the possibility of disease complications and informing the need for subsequent
imaging studies when this is clinically appropriate. Finally, for instances where CT and/or
fluoroscopic studies are indicated, radiological protocols which minimize radiation exposure
to the lowest extent possible should be utilized.(17) Indeed, Berdon and Slovis summarized a
series on radiation doses from pediatric CT by indicating that as much as 30% of the dose from
pediatric CT could be unnecessary.(41) The radiation dose from CT is being addressed on a
national level through a number of approaches including the Image Gently campaign.(42)
This analysis has a few potential limitations that should be noted. Misclassification of subjects
is always of concern when administrative claims are used as the primary data source. Both
under-ascertainment of true cases of IBD and misclassification of other diseases as IBD can
bias the results of administrative analyses. By requiring multiple diagnosis codes for either CD
or UC and including the use of IBD-specific medications in our case definition algorithm, we
attempted to optimize the sensitivity and overall accuracy of our administrative definition.
Bernstein et al have used a similar administrative definition, which was developed and
validated against primary medical record data.(43) Misclassification and/or under-
ascertainment of outcomes may also be questioned when administrative databases are used as
the primary data source. We feel that this type of bias would have a minimal effect upon our
results as prior works have demonstrated that administrative claims are reliable when studying
procedures that are highly linked to reimbursement, such as diagnostic testing, and are
comparable to data found in medical records.(44–46)
An additional limitation of this study is that the timing of the exposure in relation to the outcome
cannot be determined in a cross sectional analysis. We believe this to be of little consequence
in our study because the burden of ionizing radiation exposure remains substantial regardless
of whether the imaging was performed before, during, or after the IBD diagnosis. Also,
administrative data contain a paucity of clinical information, such as disease phenotype, extent,
severity, and time from diagnosis. These characteristics may be important in identifying
children who are more likely to be exposed to multiple diagnostic tests over the course of their
disease. A final limitation to our study is that we did not have sufficient detail to determine
whether each diagnostic procedure was medically necessary or informative. However, we did
find that 13% of CD patients and 7% of UC patients with apparently mild disease (no oral
steroid use, ED encounter, hospitalization, or surgery) were exposed to moderate diagnostic
radiation over the time period of this study. It is possible that some of the imaging performed
on these patients without obvious risk factors may have been avoidable. Indeed, the overuse
of diagnostic testing including CT has been reported in the pediatric ED setting.(47) However,
a negative imaging study can also prevent unnecessary therapeutic interventions or inpatient
admissions.
Our study has several strengths that add to prior work in this area. This is the largest, population-
based study of diagnostic radiation utilization in pediatric IBD subjects. The geographical
diversity of the study population and the inclusion of patients insured by a number of different
health plans of varying structure and size make these results broadly generalizable to the
commercially insured population of the United States. In addition, the large sample size in this
study allowed us to examine the use and drivers of diagnostic testing in pediatric UC and CD
patients separately, an important step in delineating the reasons behind the increased radiation
exposure in CD patients. An additional strength of our study is that by utilizing administrative
claims, we were able to analyze all radiologic examinations performed on each patient
regardless of the facility. Thus our study complements single center studies that only have
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access to the examinations performed at one facility and cannot capture total exposure when
imaging is performed outside of that center.
Over 2 years, a substantial proportion of children with IBD were exposed to ionizing radiation
as a result of diagnostic testing. A lifetime of diagnostic testing will magnify the risk. Children
with IBD may be seen in numerous care settings, and it is imperative that providers at all levels
of care are aware of the potential carcinogenic effects of medical radiation. Providers must
communicate with each other to coordinate a plan for the diagnosis and management of IBD
in children that considers both the risks of diagnostic and therapeutic decisions, as well as the
life-long nature of the disease. While the individual risk of diagnostic radiation exposure to
any one child is small, and the risk-benefit ratio generally favors diagnostic testing, the
increasingly large number of exposed children may create a public health concern in the future.
It is imperative that providers work together to reduce the radiation dose in pediatric exams,
reduce the amount of unnecessary diagnostic testing, and increase the use alternative imaging
modalities and/or watchful waiting when appropriate in the management of childhood IBD.
1. WHAT IS CURRENT KNOWLEDGE
Adults with inflammatory bowel diseases (IBD) are increasingly exposed to diagnostic
medical radiation
Less is known about medical radiation exposure in the community, especially in children
Ionizing radiation, including diagnostic medical radiation, may increase malignancy risk
Children are more vulnerable to the effects of ionizing radiation than adults
2. WHAT IS NEW HERE
In only 2 years, almost one-third of children with IBD were exposed to moderate diagnostic
medical radiation
Computed Tomography was used more often than has been seen in studies of adults with
IBD
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Over the two year period, 1275 studies were performed in children with UC and 2137 were
performed in children with CD. X-rays were the most commonly ordered study, comprising
60% and 48% of the studies performed in children with UC and CD, respectively. CT scans
comprised 25% of the total imaging in children with UC and 28% in children with CD.
Fluoroscopic exams were the least commonly ordered study (16% of studies in children with
UC and 23% of studies in children with CD).
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Table 2
Type of Imaging Studies and Percent Receiving Studies, Crohn’s Disease
Study Type Percent (%)
Receiving Study
Study Type Percent (%)
Receiving Study
CT* or CTA† of the
Abdomen and/or Pelvis
CT or CTA of the
Head, Neck Extremities
  No studies 69.6   No studies 95.1
  1 study 17.7   1 study 3.9
  ≥2 (maximum 11) 12.6   ≥2 (maximum 4) 0.9
UGI‡, SBFT§ or
Contrast Enema
CT or CTA of the
Chest
  No studies 62.0    No studies 97.9
  1 study 30.9   1 study 2.0
  ≥2 (maximum 5) 7.2   ≥2 (maximum 3) 0.1
Enteroclysis IVP# or VCUG**
  No studies 98.8   No studies 99.9
  1 study 1.0   1 study 0.1
  ≥2 (maximum 3) 0.2
ERCP or Cholangiogram Pelvis X-ray
  No studies 99.6   No studies 97.4
  1 study 0.2   1 study 2.6
  ≥2 (maximum 3) 0.2
Fistulogram or Sinogram Chest X-ray
  No studies 99.5   No studies 74.1
  1 study 0.4   1 study 16.1
  ≥2 (maximum 2) 0.1   ≥2 (maximum 13) 9.8
Abdominal X-ray Bone Mineral Density
  No studies 76.3   No studies 93.2
  1 study 14.0   1 study 6.1
  ≥2 (maximum 33) 9.7   ≥2 (maximum 4) 0.7
*
CT = computed tomography
†
CTA = computed tomography angiogram
‡
UGI = upper GI series
§
SBFT = small bowel follow through
#
IVP = intravenous pyelogram
**
VCUG = voiding cystourethogram
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Table 3
Type of Imaging Studies and Percent Receiving Studies, Ulcerative Colitis
Study Type Percent (%)
Receiving Study
Study Type Percent (%)
Receiving Study
CT* or CTA† of the
Abdomen and/or Pelvis
CT or CTA of the
Head, Neck Extremities
  No studies 82.2   No studies 92.8
  1 study 10.5   1 study 5.7
  ≥2 (maximum 13) 7.3   ≥2 (maximum 4) 1.4
UGI‡, SBFT§ or
Contrast Enema
CT or CTA of the
Chest
  No studies 76.4   No studies 97.5
  1 study 19.4   1 study 1.6
  ≥2 (maximum 6) 4.1   ≥2 (maximum 7) 1.0
Enteroclysis IVP# or VCUG**
  No studies 99.8   No studies 99.8
  1 study 0.2   1 study 0.2
ERCP or Cholangiogram Pelvis X-ray
  No studies 99.0   No studies 97.3
  1 study 0.8   1 study 2.2
  ≥2 (maximum 3) 0.2   ≥2 (maximum 3) 0.5
Fistulogram or Sinogram Chest X-ray
  No studies 99.8   No studies 79.1
  1 study 0.2   1 study 13.0
  ≥2 (maximum 23) 8.0
Abdominal X-ray Bone Mineral Density
  No studies 78.3   No studies 95.5
  1 study 9.2   1 study 3.7
  ≥2 (maximum 44) 12.4   ≥2 (maximum 2) 0.8
*
CT = computed tomography
†
CTA = computed tomography angiogram
‡
UGI = upper GI series
§
SBFT = small bowel follow through
#
IVP = intravenous pyelogram
**
VCUG = voiding cystourethogram
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Table 4
Factors associated with receipt of moderate dose imaging*
Ulcerative Colitis Crohn’s Disease
OR†(95% CI)‡ OR† (95% CI)‡
Age >10 1.05(0.57–1.93) 0.70 (0.42–1.19)
Gender (male) 0.74(0.49–1.14) 0.80 (0.59–1.10)
Region (east)
  South 1.43(0.84–2.86) 1.57 (1.02–2.40)
  Midwest 1.59(0.92–2.76) 1.07 (0.71–1.60)
  West 1.16(0.60–2.26) 1.37 (0.86–2.17)
Hospitalization 3.04(1.84–5.03) 4.89 (3.37–7.09)
Surgery 4.13(1.85–9.22) 2.93 (1.59–5.39)
ED§ Encounter 3.27(2.13–5.01) 2.65 (1.93–3.64)
Oral Steroids 1.50(0.86–2.60) 2.25 (1.50–3.38)
Budesonide -- 1.80 (1.10–3.06)
Immunomodulators# 0.86(0.51–1.45) 0.67 (0.47–0.97)
Anti-TNF Agents** -- 0.97 (0.62–1.51)
Oral Salicylates 1.00(0.62–1.62) 0.81 (0.58–1.13)
Rectal Salicylates 0.85(0.51–1.43) 0.75 (0.37–1.49)
*
Estimates from multi-variable logistic regression models adjusted for all other factors simultaneously
†
OR = Odds Ratio
‡
95% CI = 95% Confidence Interval
§
ED = Emergency Department
#
Includes Azathioprine, 6-Mercaptopurine, and Methotrexate
**
Includes Infliximab and Adalimumab
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